ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,101.24
-0.29%
Dow Jones
44,424.25
-0.32%
US Dollar vs MXN
20.4216
0.72%
Brent Oil
77.155
-0.04%
Bitcoin
101,321.53
-1.31%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Cassava Sciences Inc (SAVA) Cotización

Cassava Sciences Inc

Cassava Sciences Inc (SAVA)

NASDAQ
2.52
-0.01
(-0.40%)
Cerrado 26 Enero 3:00PM
Delayed by 15 minutes
2.5198
-0.0002
(-0.01%)
Fuera de horario: 6:55PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
2.5198
Postura de Compra
2.50
Postura de Venta
2.52
Volume Operado de la Acción
2,213,917
2.47 Rango del Día 2.665
2.23 Rango de 52 semanas 42.20
Capitalización de Mercado [m]
121.229M
Precio Anterior
2.53
Precio de Apertura
2.55
Hora
1000
@
2.5198
(formt)
Última hora de negociación
Volumen financiero
US$ 5,652,791
Precio Promedio Ponderado
2.5533
Volumen promedio (3 m)
6,208,570
Acciones en circulación
48,110,475
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.01
Beneficio por acción (BPA)
-2.02
turnover
-
Beneficio neto
-97.22M

Acerca de Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnosti... Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.cassavasciences.com
Sede
Wilmington, Delaware, USA
Fundado
-
Cassava Sciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SAVA. The last closing price for Cassava Sciences was US$2.53. Over the last year, Cassava Sciences shares have traded in a share price range of US$ 2.23 to US$ 42.20.

Cassava Sciences currently has 48,110,475 shares in issue. The market capitalisation of Cassava Sciences is US$121.72 million. Cassava Sciences has a price to earnings ratio (PE ratio) of -0.01.

Flujo de Opciones Cassava Sciences (SAVA)

Ver flujo de opciones completo

Flujo General

Pesimista

Prima Neta

-45k

Calls / Puts

0.00%

Comp. / Vent.

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

SAVA Últimas noticias

Más noticias

The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA

The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA PR Newswire NEW YORK, Jan. 23, 2025 NEW...

23 Enero 2025
PR Newswire (US)

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, Jan. 20, 2025 NEW YORK, Jan. 20, 2025...

20 Enero 2025
PR Newswire (US)

Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025 /PRNewswire/...

16 Enero 2025
PR Newswire (US)

Contact The Gross Law Firm by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc.(SAVA)

Contact The Gross Law Firm by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc.(SAVA) PR Newswire NEW YORK, Jan. 13, 2025 NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The...

13 Enero 2025
PR Newswire (US)

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025...

09 Enero 2025
PR Newswire (US)

Form 8-K - Current report

07 Enero 2025
Edgar (US Regulatory)

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA PR Newswire NEW YORK, Jan. 6, 2025...

06 Enero 2025
PR Newswire (US)

Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA

Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA PR...

02 Enero 2025
PR Newswire (US)

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Dec. 30, 2024 NEW YORK, Dec. 30, 2024 /PRNewswire/...

30 Diciembre 2024
PR Newswire (US)

The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire NEW YORK, Dec. 26, 2024 NEW YORK, Dec. 26, 2024...

26 Diciembre 2024
PR Newswire (US)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.2002-7.360294117652.722.782.515157692.67329341CS
4-0.0202-0.7952755905512.543.182.2731149822.72240064CS
12-23.2902-90.237117396425.8133.982.2362085706.41132136CS
26-9.4702-78.984153461211.9942.22.23411189013.43799452CS
52-23.7302-90.400761904826.2542.22.23268133114.17071442CS
156-31.4102-92.573533745933.9362.492.23191054822.19508474CS
260-5.2002-67.36010362697.72146.161.11304177533.35694748CS

SAVA - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Cassava Sciences?
El precio actual de las acciones de Cassava Sciences es US$ 2.5198
¿Cuántas acciones de Cassava Sciences están en circulación?
Cassava Sciences tiene 48,110,475 acciones en circulación
¿Cuál es la capitalización de mercado de Cassava Sciences?
La capitalización de mercado de Cassava Sciences es USD 121.72M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Cassava Sciences?
Cassava Sciences ha negociado en un rango de US$ 2.23 a US$ 42.20 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Cassava Sciences?
El ratio precio/beneficio de Cassava Sciences es -0.01
¿Cuál es la moneda de reporte de Cassava Sciences?
Cassava Sciences presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Cassava Sciences?
El último beneficio anual de Cassava Sciences es USD -97.22M
¿Cuál es la dirección registrada de Cassava Sciences?
La dirección registrada de Cassava Sciences es CORPORATION TRUST CENTER, 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Cassava Sciences?
La dirección del sitio web de Cassava Sciences es www.cassavasciences.com
¿En qué sector industrial opera Cassava Sciences?
Cassava Sciences opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

SAVA Discussion

Ver más
Steady_T Steady_T 3 semanas hace
Something's afoot.... I think it's called pump and dump.
👍️ 1 🤣 2
urge2surge urge2surge 4 semanas hace
Nervous? Just the messenger.. Volume suggests something's afoot imo.
Proven?? You sure about that?
💀 1 🤢 1 ☠️ 1
sunspotter sunspotter 4 semanas hace
Why would any proper pharma company buy a scammy company with a drug candidate proven to be ineffective?

I think we can all safely discount those “rumors”.
👍️ 1
urge2surge urge2surge 4 semanas hace
Biogen buyout rumors. Going to be a huge volume day here!
👍️0
urge2surge urge2surge 1 mes hace
Keep in mind the grand canyon gap on the chart. The reward to risk here favors upside including fomo momo.
👍️0
urge2surge urge2surge 1 mes hace
No ideas on what catalyst could be in play but there's short covering and institutional buying back in. Last day of tax loss selling is also fueling the buys. The obv is clearly indicating accumulations. Just my take
👍️0
ranchhand71 ranchhand71 1 mes hace
Or maybe this is year end retail flush dump capitulation… has the company downsized the staff in Austin? Any idea what their next act is?
👍️0
Steady_T Steady_T 1 mes hace
Based on what? Short squeeze could be epic here.
👍️0
urge2surge urge2surge 1 mes hace
Looks like bottom is in. Short squeeze could be epic here.
👍️0
ranchhand71 ranchhand71 2 meses hace
Majority of employees to be laid off?
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
Maybe they can save the company by saying they will turn into an AI drug discovery company and put their cash in BTC?
LOL
👍️0
ranchhand71 ranchhand71 2 meses hace
Delusional!
👍️ 1
sunspotter sunspotter 2 meses hace
Yes, a company founded and run by fraudsters with a drug that doesn’t work.

What could possibly go wrong?
👍️ 1
ttottip ttottip 2 meses hace
It's worth it to take a position here. There's a chance for rebound here.
😂 1
ranchhand71 ranchhand71 2 meses hace
In SEC 144 filing CFO using Morgan Stanley to sell SAVA stock . Saying he knows no material info!!!! Hmmm..
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
You are most welcome.
Maybe he is good at sniffing out security fraudsters and crooks because he knows how to think like them.
Regards...
👍️0
TheFinalCD TheFinalCD 2 meses hace
THANKS for the reply

I cant stand that weirdo either

he just happened to make a good call on $SAVA whether it was really him or not

who knows
👍️0
tredenwater2 tredenwater2 2 meses hace
What about the director who poured millions into Cassava propping it up when it would crash from bad news? If this was a scam, wouldnt he have known about it?
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
That also baffled me. Many smart people had their money tied up here and somehow the share price recovered after the court cases in September. Id love to know more about the why.
They didnt see the forest for all the trees?
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
I can only agree. Shkreli still has friends in the industry that likely told him about all of his "DD" that he presented in this rink dink "paper" then earns the laurels.
98% of PH3 Alzheimer trials miss and this one had many sticks in the soup. --> managements history of lying and no peer reviewed literatue backing.
Unbelievable there is this laughable antihero worshipping around his persona. Nothing fabulous about this sociopath.
👍️ 1
Hoskuld Hoskuld 2 meses hace
I made the same call repeatedly over the last 2 years but didn't get the love that the convicted fraudster is getting!
👍️ 1
ranchhand71 ranchhand71 2 meses hace
How long before indictments of former CEO and his wife? Class action suit? Who sold with inside info this past Friday?
👍️0
TheFinalCD TheFinalCD 2 meses hace
I dont like him but he made a good pre P3 call
if somehow it passed P3 it could have went up slot
P3 fail it crashed


Im listening to him talk about shorting MSTR against BTC hedge/arbitrage
https://x.com/i/broadcasts/1LyxBgywQZkKN
👍️0
MartinLutherKing MartinLutherKing 2 meses hace
Last call all aboard SAVA FDA fast track status Micro RNA novel prize cancer destruction RNAZ
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
When companies split in ways that put them this far above the minimum requirement they usually do so when they expect much more downside and when they want to cater to the low float crowd instead of real investors in the bio space.
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
Thank you. Someone forwarded this to me, else i wouldnt have anticipated something like that :)
Im not interested in ESPR right now as its really in no mans land. I dont "hold" many bios at all. The market has been brutal past few months. But there are some 70 stocks i monitor daily for action...
👍️0
FooBarAndGrill FooBarAndGrill 2 meses hace
$PGHL. Wow! Ran 918% during market hours. AH down 87%.
The opposite of a bear raid.
Prada
9 hours ago

So what happened? I’ll tell you….

Short sellers need only be outside of margin compliance for a fraction of a second for brokers to force automatic buy-ins. Knowing this, offshore scam operators tightly control the float of all these issuers but sometimes leave borrow available to lure in short sellers...

When short sellers bite, the scam operators wash trade a spike in the stock, then keep bid/asks moving during the halt so no unhalt price can be settled upon during regular trading hours. Then, after hours, it unhalts as they rip the price 10x+, causing brokers to force-liquidate accounts that were short. Brokers buy-in to cover the short sales as scam artists sell into the artificially high price.

This can lead to short accounts being wiped out instantly and can even lead to broker losses. The same liquidation scam playbook had been executed previously with other Nasdaq offshore scam tickers such as $ZJYL.
👍️0
dinogreeves dinogreeves 2 meses hace
This is terrible

https://finance.yahoo.com/quote/PGHL/
👍️0
dinogreeves dinogreeves 2 meses hace
So much for that former insider/fraudster of KBI*O then turned into another turd HYG*N. But altogether, SAVA has been a scam, any public company that works with Maxim is a scam. Period.
👍️ 1
janice shell janice shell 2 meses hace
Yes indeed!
👍️0
FACT-MASTER FACT-MASTER 2 meses hace
Exactly.

Nice chatting with you Janice.
👍️0
janice shell janice shell 2 meses hace
Yes, I was surprised to learn kidney beans are somewhat toxic. Toxic enough that you should never cook them in the water you soaked them in. I wouldn't have known were I not an inveterate reader of packaging.
👍️0
FACT-MASTER FACT-MASTER 2 meses hace
Cassava, from what i have seen, is ingrained into the cultures of Mexican / African / South American diets and they are proud of it.

Their persistence, imo comes from a lack of alternatives and again a culture practice of growing a usable and edible product. Visiting some places in Mexico / Brazil you begin to understand people are just in "survival" mode - use what's available.

The toxicity issue is also common in legume crops such as lima / red kidney beans which are also common in these cultural diets.
👍️0
janice shell janice shell 2 meses hace
And it was first done by pretty primitive people.
👍️0
nsomniyak nsomniyak 2 meses hace
Cocoa beans taste pretty crappy before you run them through a 15 step process to get chocolate...Another case of " how did they get from this raw stuff to that?"
👍️0
janice shell janice shell 2 meses hace
Yes, it was an unusual choice of name. Though it's a popular carbohydrate in Central and South America, perhaps the most popular. I've always wondered how many people died before they figured out how to prepare it. And why they were so persistent.
👍️0
FACT-MASTER FACT-MASTER 2 meses hace
Interesting, just like cassava, which when raw, contains cyanide and is toxic.

https://www.medicalnewstoday.com/articles/323756#is-it-toxic

The name picked by scammers for scammers - how suitable!

Now let's see , where is cassava grown? Mexico / Costa Rica / South America. Insiders probably went straight to the airport after the reverse split, never to be seen again, unless of couse Karma catches up to them, amen.

Appreciate the "scam force" here on Ihub - H Bear too.
👍️0
janice shell janice shell 2 meses hace
Hello again! I found this one remarkable because it was KNOWN that the most important insiders were scammers. And people seem simply to have discounted that, somehow imagining what they produced would be a winner.
👍️0
FACT-MASTER FACT-MASTER 2 meses hace
Why, hello janice!

Our paths have not crossed for a long time.

Yes, investors still gett'in burnt, will it ever end !? i think not, even i , have had to learn a few lessons from my foolish juvenile days. (lol)
👍️0
FACT-MASTER FACT-MASTER 2 meses hace
Comprende amigo,

"Its possible for mortals to anticipate a partner in a ph1/ph2 company when their data is about to be due and a BP dropped similar but not equal programs recently"

(cost efficient for a BP to partner up with a smaller biotech demonstrating a superior product in the same category)

The reverse can also be true - eg IMTX, BMY drops out of 1 trial, IMA402 p1/p2 results are poor - same press release in that instance. Was suspicion evident in previous trading - i beleive so, however, hindsight is 20/20
👍️0
janice shell janice shell 2 meses hace
Seriously, did anyone need Shkreli to tell them it was doomed? The follies of management should have been enough.
👍️ 1
FACT-MASTER FACT-MASTER 2 meses hace
Congrats on your short here with SAVA.

Your education paid off big time in this instance!

We should probably discuss ESPR further on that board, of course if you are up to that.
👍️0
FACT-MASTER FACT-MASTER 2 meses hace
Reminds me of of ARGS - that was a stinging lesson for me, ouch...still hurts!

Although i feel bad for investors in SAVA, biotech is high risk and that should be understood by all investors. Lawsuit won't help imo, ... prove wrongdoing against forward looking statements, etc, etc, for 5+ years, imo. - only good for the lawyers, imo.

Ref: Argos Therapeutics
👍️0
TheFinalCD TheFinalCD 2 meses hace
https://x.com/MartinShkreli/status/1859681514415607930
👍️0
MartinLutherKing MartinLutherKing 2 meses hace
You will all kiss my feet brothers make it all back
👍️0
MartinLutherKing MartinLutherKing 2 meses hace
Get ready for Fda fast track status for nobel prize micro rna for terminally ill cancer patients
👍️0
MartinLutherKing MartinLutherKing 2 meses hace
A reverse split is NOT something directors or management wishes to do — we all hope it won’t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
I have never ever in my life seen a great bio with a chart like this.
SCREAMS promotion campaign - which is something you dont do when you have the next greatest thing in oncology.
Now a 1 for 33 is coming??

"The reverse split will reduce the number of shares of common stock outstanding from 17,265,658 shares to approximately 523,202 shares." per their recent PR. They want to cater to the low float crowd.
A more healthy ratio wouldve done it too...
👍️0
MartinLutherKing MartinLutherKing 2 meses hace
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
October 23 2024 - 7:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the second cohort of patients based on its favorable review of Cohort 1 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer. All patients in the first cohort remain on study for continued treatment. No significant safety or dose limiting toxicities have been reported. The dose administered to the second cohort will be approximately double the dose administered to the first cohort.
“An SRC is a group of clinicians and experts that oversee the safety of subjects during the conduct of the trial. The SRC makes decisions on whether and how the study should proceed, including dose escalation and de-escalation decisions per the study design. The recommendations of the SRC are used to decide whether a clinical trial should be continued as designed, changed, or terminated,” commented Sue Duggan, TransCode’s Senior Vice President of Operations. Duggan added, “No dose-limiting toxicities were reported in the first cohort of patients treated with TTX-MC138. Eligible subjects may now be scheduled in Cohort 2 for treatment with the next dose level of TTX-MC138.”
👍️0
MartinLutherKing MartinLutherKing 2 meses hace
Is FDA And NIH Ascam
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
September 05 2024 - 7:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate. TransCode has recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors.


The clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138. While efficacy of TTX-MC138 is not an endpoint in this trial, the trial may nevertheless provide early evidence of TTX-MC138 clinical activity in patients with metastatic disease. Funds under the grant are expected to be received over two years.

“We are honored that the NIH recognizes and continues to support our mission to advance therapies against metastatic cancer,” said Zdravka Medarova, Ph.D., Chief Scientific Officer of TransCode. “NIH funding is awarded only after rigorous review. We believe that this award attests to the potential impact, novelty, and robustness of the TTX-MC138 clinical development program.”

TTX-MC138 is a first-in-class therapeutic candidate with novel relevance to metastatic disease. Successful clinical development of TTX-MC138 potentially represents a viable treatment option for many patients with metastatic cancer.
👍️0

Su Consulta Reciente

NASDAQ
SAVA
Cassava Sciences
LSE
AP94
Anz Bank.43
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados